GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celldex Therapeutics Inc (STU:TCE2) » Definitions » ROE % Adjusted to Book Value

Celldex Therapeutics (STU:TCE2) ROE % Adjusted to Book Value : -6.36% (As of Mar. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Celldex Therapeutics ROE % Adjusted to Book Value?

Celldex Therapeutics's ROE % for the quarter that ended in Mar. 2024 was -20.73%. Celldex Therapeutics's PB Ratio for the quarter that ended in Mar. 2024 was 3.26. Celldex Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 was -6.36%.


Celldex Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for Celldex Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celldex Therapeutics ROE % Adjusted to Book Value Chart

Celldex Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -115.34 -12.00 -5.30 -4.90 -7.28

Celldex Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.73 -7.22 -10.98 -10.01 -6.36

Competitive Comparison of Celldex Therapeutics's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Celldex Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Celldex Therapeutics's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celldex Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Celldex Therapeutics's ROE % Adjusted to Book Value falls into.



Celldex Therapeutics ROE % Adjusted to Book Value Calculation

Celldex Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-36.98% / 5.08
=-7.28%

Celldex Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-20.73% / 3.26
=-6.36%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Celldex Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Celldex Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Celldex Therapeutics (STU:TCE2) Business Description

Traded in Other Exchanges
Address
53 Frontage Road, Suite 220, Perryville III Building, Hampton, NJ, USA, 08827
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.

Celldex Therapeutics (STU:TCE2) Headlines

No Headlines